Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Isomyosamine - TNF Pharmaceuticals

Next Previous
Drug Profile

Isomyosamine - TNF Pharmaceuticals

Alternative Names: MYMD-1

Latest Information Update: 27 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MyMD Pharmaceuticals
  • Developer TNF Pharmaceuticals
  • Class Alkaloids; Anti-inflammatories; Antirheumatics; Pyridines; Pyrroles; Small molecules
  • Mechanism of Action Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Sarcopenia
  • Phase I Rheumatoid arthritis; Thyroiditis
  • No development reported Autoimmune disorders

Most Recent Events

  • 24 Jun 2025 TNF Pharmaceuticals plans a compassionate use (expanded access) trial for Adenosine-deaminase-deficiency
  • 02 Apr 2025 Isomyosamine is still in phase-I development in Thyroiditis(In volunteers) in USA (PO, Capsule) (MyMD Pharmaceuticals pipeline, April 2025)
  • 02 Apr 2025 Phase-I clinical trials in Rheumatoid arthritis in USA (PO), before April 2025 (MyMD Pharmaceuticals pipeline, April 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top